What should be the best approach post-liver resection in non-viral non-cirrhotic hepatocellular carcinoma?  

作　　者：Mariana Verdelho Machado 

机构地区：[1]Serviço de Gastrenterologia,Hospital de Vila Franca de Xira,Lisboa,Portugal [2]Faculdade de Medicina,Universidade de Lisboa,Lisboa,Portugal

出　　处：《Hepatobiliary Surgery and Nutrition》2024年第3期554-556,共3页肝胆外科与营养（英文）

摘　　要：Hepatocellular carcinoma(HCC)is the sixtieth most prevalent cancer and the third cause of cancer-related mortality worldwide(1).HCC occurs in the context of liver disease,with around 85%of liver cancers developing in the set of liver cirrhosis(2).However,the proportion of non-cirrhotic HCC is not transversal across the etiologies of liver disease,with HCC occurring in patients with metabolic-associated steatotic liver disease(MASLD)being five times more likely to occur in non-cirrhotic livers.Indeed,2 out of 5 MASLD-associated HCC patients are non-cirrhotic.With the changing landscape of etiologies of advanced liver disease we are assisting in the last decade,with a decline in hepatitis B or C virus liver disease and an increase in MASLD,we can foresee an increase in the burden of non-cirrhotic HCC(3).However,our accumulated knowledge on the prognosis and treatment strategies for HCC relies mostly from cirrhotic patients,which does not allow truly evidence-based decisions in the set of non-cirrhotic HCC.

关 键 词：cirrhotic MORTALITY LIKELY 

分 类 号：R735.7[医药卫生—肿瘤]